RondinX’ Microbiome Platform Builds on an Exclusive License from the Weizmann Institute of Science and Research Collaborations with the Elinav and Segal Labs )–RondinX, an emerging pioneer in intelligent microbiome drug development, today unveiled a novel approach to discovering how changes in the human microbiome affect health and disease. RondinX’ cloud-based technology platform adds a new dimension to the microbiome drug development process by profiling and predicting microbial growth dynamics from single metagenomic samples.